Vitamin C trial shows no effect on cell growth, but survival signal emerges in early blood disorders
A daily vitamin C supplement did not slow abnormal blood cell growth in a phase 2 trial, yet the intervention produced a pattern clinicians will not ignore: favorable inflammatory shifts, fewer serious complications, and a lower death count during follow-up. The study focused on people with clonal cytopenia of undetermined significance or lower-risk myeloid malignancies, a population that sits close to the threshold between chronic blood abnormality and overt cancer. In that setting, even a modest biologic signal can matter because the disease course is often prolonged, uncertain, and shaped by inflammation as much as by cell counts.
Vitamin C entered this space for a reason. The vitamin can increase the activity of TET enzymes, which help regulate gene expression through epigenetic mechanisms, and reduced TET activity is a recurring feature in some blood cancers. That biology gave investigators a plausible target: if vitamin C could restore part of that enzymatic function, it might alter disease behavior before full malignant transformation. The EVITA trial tested that hypothesis directly.
Randomized EVITA design tested 1,000 mg daily for 12 months
The randomized, double-blind, placebo-controlled trial enrolled 109 participants in Denmark and the United States. Fifty-five participants received oral vitamin C at 1,000 mg per day, while 54 received placebo, and treatment continued for 12 months. The study’s primary question was straightforward: would vitamin C change the growth rate of precancerous or cancerous blood cells? On that endpoint, the two groups were similar, which means the supplement did not deliver the disease-control effect researchers had hoped to see.
That result matters because it separates cell proliferation from the broader clinical picture. A therapy can fail to slow abnormal clone growth and still influence the inflammatory milieu, susceptibility to infection, bleeding risk, or marrow resilience. In early myeloid disorders, those downstream effects can shape quality of life and, potentially, survival more than a laboratory count alone would suggest.
Inflammation, anemia, and infection moved in a favorable direction
Participants taking vitamin C showed changes in inflammatory signaling that aligned with better outcomes. The trial also recorded fewer cases of anemia, pneumonia, acute aseptic arthritis, and internal bleeding in the vitamin C group. Those clinical events point toward a possible biologic role beyond antioxidant branding or dietary supplementation. Inflammation can suppress erythropoiesis, distort innate immune responses, and make fragile marrow states less stable; if a treatment dampens that inflammatory drive, it may reduce the complications that often send these patients back to clinic or hospital.
Gastrointestinal problems were more common with vitamin C, a reminder that even a familiar supplement can carry tradeoffs when used in a structured clinical trial. The adverse-event pattern was not described as prohibitive, but it was not negligible either. In a population already coping with chronic hematologic disease, tolerability matters because adherence over 12 months depends on whether patients can stay on therapy without adding another burden to daily life.
Follow-up deaths were fewer in the vitamin C arm
At a median follow-up of 33.6 months, 35 participants had died in the intention-to-treat population. Twenty-four deaths occurred in the placebo group and 11 in the vitamin C group. An exploratory analysis found that participants assigned to vitamin C were more likely to survive during follow-up than those who received placebo.
The death imbalance is striking, but it must be treated with caution. This was an exploratory finding from a phase 2 trial, not a definitive survival study, and the sample size was small. Still, the direction of effect aligns with the rest of the signal: less inflammation, fewer serious complications, and a lower death count in the supplement arm. In early blood disorders, survival can worsen through infection, bleeding, marrow failure, or progression to more aggressive disease, so a therapy that influences any part of that pathway deserves a larger confirmatory trial.
Why epigenetics makes the result biologically plausible
The mechanistic rationale centers on TET enzymes, which depend on vitamin C to function optimally. These enzymes participate in epigenetic regulation, the machinery that determines which genes are switched on or off without altering the DNA sequence itself. In myeloid disease, that layer of control is often disrupted. If vitamin C can improve TET activity, it could partially restore gene regulation in a way that lowers inflammatory signaling or blunts the tempo of disease evolution, even if it does not visibly shrink the abnormal clone over 12 months.
That kind of mechanism fits the trial pattern better than a simple anticancer narrative. The supplement did not act like a cytotoxic drug. Instead, it appeared to influence the biological environment in which the disease exists, which may explain why the most visible differences showed up in complications and survival rather than in the primary growth endpoint.
Larger confirmation trial remains the gatekeeper
The investigators were explicit that the findings are encouraging but not ready to support treatment recommendations. A larger phase 3 trial will be needed to determine whether the apparent survival advantage is real, whether it persists across broader patient groups, and whether the inflammatory changes translate into durable clinical benefit. The current study also leaves open the question of which subgroup, if any, benefits most — patients with clonal cytopenia, lower-risk myeloid malignancies, or those with particular epigenetic profiles.
For now, the trial offers a disciplined signal rather than a practice-changing answer. Vitamin C did not slow abnormal blood cell growth, but it was linked to a more favorable inflammatory profile, fewer complications, and fewer deaths during follow-up. The next study will need to determine whether those findings hold up when the sample size is large enough to separate chance from genuine therapeutic effect.